Amicus Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Amicus Therapeutics has a total shareholder equity of $132.5M and total debt of $388.9M, which brings its debt-to-equity ratio to 293.5%. Its total assets and total liabilities are $749.5M and $617.0M respectively.
Key information
293.5%
Debt to equity ratio
US$388.94m
Debt
| Interest coverage ratio | n/a |
| Cash | US$260.06m |
| Equity | US$132.52m |
| Total liabilities | US$616.96m |
| Total assets | US$749.48m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0HF9's short term assets ($461.7M) exceed its short term liabilities ($168.1M).
Long Term Liabilities: 0HF9's short term assets ($461.7M) exceed its long term liabilities ($448.9M).
Debt to Equity History and Analysis
Debt Level: 0HF9's net debt to equity ratio (97.2%) is considered high.
Reducing Debt: 0HF9's debt to equity ratio has increased from 24.8% to 293.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0HF9 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 0HF9 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.